Genome Biologics provides TrueCardium® human cardiac organoids and screening services for cardiotoxicity testing, disease modeling, and translational efficacy studies - delivering integrated, tissue-level human insights beyond conventional in vitro assays and animal models.
Human Cardiac Organoid Screening & Disease Modeling Services
Predict cardiotoxicity, validate therapeutic targets, and test efficacy in TrueCardium® human cardiac organoids - the most physiologically advanced multicellular heart organoid platform available for translational drug development.
Genome Biologics provides end-to-end cardiac safety pharmacology and disease-model screening services for pharmaceutical and biotechnology partners seeking more predictive, human-relevant data beyond conventional 2D assays and animal models.
TrueCardium® has been reviewed in regulatory contexts by BfArM (Germany) and the U.S. FDA as part of integrated nonclinical pharmacology packages supporting clinical translation.
TrueCardium® Services Include:
- Cardiotoxicity & QT liability screening
- HFpEF, fibrosis, inflammation, rare disease models
- Multi-omics mechanism-of-action profiling
- Regulatory-ready reporting and endpoints
Cardiac Organoid Services for Drug Discovery and Safety
Genome Biologics delivers CRO-style study packages using TrueCardium® human cardiac organoids, supporting decision-making across discovery, preclinical development, and translational research.
Core Service Offerings
Cardiotoxicity & QT Liability Screening
Detect functional and structural cardiac risk early using human-relevant endpoints.
Disease Model Efficacy Studies
Test therapeutics in validated models of HFpEF, fibrosis, inflammation, and cardiometabolic disease.
Mechanistic Profiling & Multi-Omics Analytics
Generate deep biological insight through transcriptomics, proteomics, metabolomics, and biomarker discovery.
Custom Study Design & Partnership Programs
Tailored screening workflows, endpoint selection, and reporting aligned to your program goals.
TrueCardium® Platform Overview
TrueCardium®: Advanced Human Cardiac Organoids
TrueCardium® is a multicellular, vascularised, innervated and functionally mature human cardiac organoid platform derived from iPSCs and engineered to capture complex heart biology in three dimensions.
Engineered to capture the cellular complexity of native human cardiac tissue, TrueCardium® integrates:
- Cardiomyocytes, endothelial cells, fibroblasts, neurons, and immune components
- Physiological contractility and metabolic maturation
- Clinically meaningful stress and disease responses
- Scalable workflows for screening and translational efficacy testing
By integrating cardiomyocytes with endothelial, neuronal, stromal, mural, and immune cell populations, TrueCardium® recreates key aspects of cardiac tissue complexity, enabling evaluation of intercellular signaling and coordinated tissue-level responses that are difficult to assess in reduced cellular models. This enables more meaningful assessment of drug efficacy, safety, and remodeling biology in a human-relevant cardiac microenvironment.
TrueCardium® bridges the gap between in vitro assays and patient outcomes - enabling more predictive cardiovascular drug development.
Key Applications
Genome Biologics supports partners across major cardiovascular development needs:
Cardiotoxicity Screening
Identify drug-induced cardiac injury, arrhythmia risk, and mitochondrial liabilities early with predictive human organoid endpoints.
Disease Modeling & Mechanistic Studies
Model HFpEF, diabetic cardiomyopathy, fibrosis, inflammation-driven remodeling, and rare genetic cardiomyopathies in human-relevant systems.
Personalized Medicine & Patient Stratification
Evaluate drug responses across diverse genetic backgrounds using patient-specific iPSC-derived organoids.
Advanced Analytics
Integrate functional assays with multi-omics and AI-supported interpretation for mechanism-of-action and biomarker discovery.
Validated Disease & Stress-Induced Cardiac Models
We offer established and custom TrueCardium® disease platforms, including:
- HFpEF and cardiometabolic dysfunction
- Inflammation-driven remodeling and CHIP-associated phenotypes
- Ischemic injury and hypoxia-reperfusion stress
- Mitochondrial cardiomyopathies
- Rare and orphan cardiovascular diseases
These models enable therapeutic efficacy testing in complex human cardiac tissue environments where animal models often fail to translate.
Comprehensive Functional and Molecular Readouts
TrueCardium® studies include robust endpoints aligned with cardiac safety pharmacology and translational efficacy:
- Viability, cytotoxicity, cardiac injury biomarkers (hsTnT, LDH)
- Contractility, calcium handling, electrophysiology
- Mitochondrial function and metabolic flux (Seahorse OCR/ECAR)
- Fibrosis, inflammation, and stress pathway activation
- Bulk RNA-seq, single-cell and spatial transcriptomics
- Proteomics, metabolomics, biomarker panels
Studies encompassing dose-response profiling, functional endpoints, and decision-grade reports are typically delivered within 2 - 6 weeks.
Why Partner With Genome Biologics?
- Human-relevant cardiac organoids with multicellular complexity
- Predictive NAM-aligned alternative to animal testing
- Regulatory-facing evaluation experience (FDA, BfArM contexts)
- Expertise spanning cardiovascular disease biology and CRO execution
- Customisable service packages with decision-grade reporting
We work as an extension of your development team — delivering high-confidence data to accelerate safer and more effective cardiovascular therapies.
Ready to Generate Predictive Human Cardiac Data?
Whether you are advancing a new chemical entity or evaluating cardiac safety liabilities, or testing efficacy in complex disease models, Genome Biologics delivers predictive human cardiac organoid data to accelerate safer and more effective therapies.
Request a study proposal to receive a tailored screening plan, timeline, and deliverables from our scientific team.
Genome Biologics is recipient of the European Union H2020 SME Instrument Phase 1, Phase 2 and the EIC Accelerator award
Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a leading life science incubator program. JLABS serves as a global network of open innovation ecosystems, empowering innovators, including biotech startups, to create and accelerate the delivery of life-enhancing health and wellness solutions to patients worldwide.
Copyright © 2026 Genome Biologics – Human Cardiac Organoid Platform | TrueCardium® - All Rights Reserved.
This site uses cookies.
We use cookies to analyze website traffic and to optimize your user experience for this website. If you accept cookies, your data will be merged with that of other users.